SCHEMBL13620380

SCHEMBL13620380

N#Cc1cccc(Cl)c1Cn1c(=O)[nH]c2cnc(NCCCN)nc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 4/20 0.47
JAK3 P52333 4/20 0.47
USP1 O94782 3/20 0.38
EGFR P00533 3/20 0.36
FGFR1 P11362 3/20 0.36
ADORA3 P0DMS8 1/20 0.36
TLR7 Q9NYK1 4/20 0.35
PAK1 Q13153 1/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2B Q13224 1/20 0.34
ACP1 P24666 1/20 0.34
SRC P12931 1/20 0.34
FGFR2 P21802 1/20 0.34
FGFR4 P22455 1/20 0.34
FGFR3 P22607 1/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2270517 0.91 JAK2 (0.47) JAK2JAK3USP1EGFRFGFR1
SCHEMBL13608332 0.88 JAK2 (0.46) JAK2JAK3USP1EGFRFGFR1
SCHEMBL12371651 0.87 JAK2 (0.45) JAK2JAK3USP1EGFRFGFR1
SCHEMBL13608206 0.85 GRIN1 (0.44) JAK2JAK3USP1GRIN1GRIN2B
SCHEMBL13608238 0.85 JAK2 (0.45) JAK2JAK3USP1EGFRFGFR1
SCHEMBL12371654 0.83 JAK2 (0.39) JAK2JAK3USP1EGFRFGFR1
SCHEMBL12371660 0.82 PRKCQ (0.46) JAK2JAK3USP1EGFRFGFR1
SCHEMBL12371665 0.82 JAK2 (0.51) JAK2JAK3USP1TLR7
SCHEMBL13608336 0.81 PIK3CD (0.42) JAK2JAK3USP1EGFRFGFR1
SCHEMBL12371668 0.81 JAK2 (0.45) JAK2JAK3USP1EGFRFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090281075-A1 ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS PHARMACOPEIA, INC. (US) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281075-A1 ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS PRKCE, PRKCZ, PRKCQ JAK2 1072/4885JAK3 1062/4885USP1 3253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.